Pasithea Therapeutics Corp. (KTTA)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$50.5M
Cash & Equivalents
$4.8M
Quarterly Burn Rate
32 mo
Est. Cash Runway
$16M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT06299839 PAS-004 in Patients With Advanced Solid Tumors PHASE1 Recruiting 48
NCT06961565 PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas PHASE1 Recruiting 56

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for KTTA.

SEC EDGAR Filings

All SEC filings for Pasithea Therapeutics Corp. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.